Seeking Patient Care?
Dr. C. Ola Landgren has assembled a team of physicians and researchers from world-class facilities around the country. Under his leadership of the newly formed Myeloma Institute, the team consistently publishes impactful studies and influences opinions on how to manage the disease. The Institute allows our team to be hyper-focused, unified, and well-supported in our mission to transform outcomes for people suffering with myeloma.
Among Dr. Landgren’s research focuses are studies like TRANSFORMM, which is open for recruitment and focuses on learning how to prevent multiple myeloma by identifying early signs in patients’ genes. Prevention is key, according to Dr. Landgren, because there are no established curative therapies to treat multiple myeloma, but there could be more options if scientists can eradicate the disease before it takes hold. Dr. Landgren also leads multi-institutional efforts to change the management of myeloma by assessing combination treatments utilizing immunotherapies, like the ADVANCE trial, and cutting-edge novel treatments. As head of the Institute, he directly oversees all of the research efforts and acquires cutting-edge research tools such as immune-imaging to scan for disease with exquisite sensitivity, circulating tumor DNA assays to track the disease in the blood, and mass spectroscopy for the characterization of myeloma proteins.
As Associate Director, Dr. Dickran Kazandjian has a passion for novel approaches including immunotherapies and early therapies. His experience working at the Food and Drug Administration (FDA) and National Cancer Institute has helped the Institute to open Phase 1 and Phase 2 clinical trials for promising new drugs, including first-in-class therapies, and to attract support from pharmaceutical companies to offer treatments available at only select sites across the country.
As Associate Director, Dr. Francesco Maura of Dr. Landgren’s Genomics laboratory uses technologies such as whole genome sequencing to identify people with early signs of myeloma that may be likely to progress to myeloma. The Genomics lab leverages sequencing technologies and machine learning to understand how myeloma develops, provide more accuracy to prognostication, and to identify new targets and disease processes.